The prospect of deep Medicaid cuts has become a flashpoint in Congress, with leaders of both parties accusing their counterparts of lying.

Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...

NCI employees received internal guidance last week to flag manuscripts, presentations, or other communications for scrutiny if they addressed “controversial, high profile, or sensitive” topics.

(HealthDay News) — Seventeen percent of American adults surveyed said they want to see Medicaid funding decreased, while 42% said funding should increase, and 40% said it should be kept about the same ...

It is imperative to align strategies that can prevent ovarian cancer while also strengthening support for patients, caregivers, and health systems that are confronted by it,” the researchers wrote.

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Several studies have suggested that COVID-19 may increase a person’s risk of developing cancer or promote metastasis of existing cancer.

The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

A new report details how many people in each state would lose access to Medicaid if Republicans in Congress were to cut the program by one-third.